A Two-Part Clinical Study to Evaluate the Effects of Multiple Doses of Itraconazole on the Single-Dose Pharmacokinetics of MK-2828 (Part 1) and Multiple Doses of MK-2828 on the Single-Dose PK of Midazolam (Part 2) in Healthy Participants
Merck Sharp & Dohme LLC
Summary
The main goals of this study are: * To learn what happens to one dose of MK-2828 in a healthy person's body over time when it is taken with itraconzole * To learn what happens to one dose of midazolam in a healthy person's body over time when it is taken with MK-2828 Researchers want to learn if the levels of MK-2828 in the body are about the same when MK-2828 is taken with itraconazole as when it is taken alone. They also want to know if taking MK-2828 more than once affects how much midazolam is in the body after a single dose.
Eligibility
- Age range
- 24–60 years
- Sex
- All
- Healthy volunteers
- Yes
Inclusion Criteria: The main inclusion criteria include but are not limited to the following: \- Participant is in good health Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * History of cancer (malignancy) * History of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
Interventions
- DrugMK-2828
Administered orally as capsule
- DrugItraconazole
Administered orally as syrup
- DrugMidazolam
Administered orally as syrup
Location
- Fortea CRU Madison ( Site 0001)Madison, Wisconsin